-
Mashup Score: 41Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer - 2 month(s) ago
Financial support: Jie Wu, Jie Wu Administrative support: Vivek Subbiah, Vivek Subbiah Provision of study materials or patients: Sireesha Yedururi, Vivek Subbia h, Sireesha Yedururi, Vivek Subbiah Collection and assembly of data: Vivek Subbiah, Vivek Subbiah Data analysis and interpretation: Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie Wu AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 36Patterns of Treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma - 5 month(s) ago
PURPOSE Medullary thyroid cancer (MTC) harbors frequent mutations in RET oncogene. Selective RET inhibitors (RETi) have emerged as effective treatments. However, resistance almost invariably occurs. METHODS MTC patients who were initiated on RETi between 2018 and 2022 were included. Baseline characteristics, RET mutational status, RETi response, available tumor tissue and molecular profiles sampled pre- and post-RETi were analyzed. RESULTS Among 46 MTC patients on RETi during the study period, 26 patients had discontinued at data cut-off because of progression (n = 16), death (n = 4), and toxicity (n = 6). The most frequent RET mutations at baseline were p.M918T (n = 29), and p.C634X (n = 6). Pre- and post-RETi molecular profiles were available in 14 patients. There was no primary resistance on pre-RETi samples. Post-RETi profiles revealed a bypass mechanism of resistance in 75% of the cases including RAS genes mutations (50%), FGFR2 and ALK fusions and and MYC p.P44L. RET solvent from
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Resistance to selective #RET inhibitors for medullary thyroid cancer in @JCOPO_ASCO. While RET solvent front and hinge region mutations noted, high rate of bypass resistance (75%) including RAS, FGFR2, ALK, MYC. Will NSCLC be similar? https://t.co/dNBy521fws
-
-
Mashup Score: 50Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer - 5 month(s) ago
Financial support: Jie Wu, Jie Wu Administrative support: Vivek Subbiah, Vivek Subbiah Provision of study materials or patients: Sireesha Yedururi, Vivek Subbia h, Sireesha Yedururi, Vivek Subbiah Collection and assembly of data: Vivek Subbiah, Vivek Subbiah Data analysis and interpretation: Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie Wu AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Exceptional responses to selpercatinib in #RET fusion-positive pancreatic cancer described in @JCOPO_ASCO. Rare but certainly actionable events! https://t.co/AQuH67uuxD
-
-
Mashup Score: 3
FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions
Source: www.fda.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Pralsetinib receives full FDA approval for #RET fusion positive NSCLC. Previous accelerated approval from the ARROW trial converted to full approval with larger dataset (n=237). 1L RR 78% with mDOR 13.4m. In later lines, RR 63%, mDOR 38.8m. https://t.co/FJIKf1TjCb
-
On 8/9/23, the @US_FDA granted regular approval to pralsetinib for adult patients w/metastatic rearranged during transfection (RET) fusion-positive #NSCLC, as detected by an FDA-approved test. Learn More: https://t.co/REfxNidRqn #LCSM https://t.co/fdpOlEOb8E
-
-
Mashup Score: 14Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series - 9 month(s) ago
Lung cancer is the leading cause of cancer-related death in both men and women with over 130,000 deaths and more than 220,000 new cases expected each year in the United States1. Eighty to ninety percent of newly diagnosed cases are Non-Small Cell Lung Cancer (NSCLC) with 50% of those being histologically adenocarcinoma2. Rearranged during Transfection (RET), a proto-oncogene coding for a tyrosine kinase receptor, was discovered in NSCLC in 2012 as on oncogenic driver 3, 4. RET fusion /rearrangement occurs 2 % of lung adenocarcinomas with most patients being never smokers and a median age of 61 years5, 6.
Source: www.clinical-lung-cancer.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Case series @ClinicalLung outlines risk of chylous ascites with selective #RET inhibitors selpercatinib and pralsetinib. Unclear mechanism; important to recognize as it could be mistaken for progression. Cases here responded to dose reduction, octreotide. https://t.co/yo5aFpDJMI
-
-
Mashup Score: 19Lilly pressures Blueprint further with positive Retevmo trial in newly diagnosed lung cancer - 9 month(s) ago
In their ongoing RET inhibitor rivalry, Eli Lilly is pulling further ahead of Blueprint Medicines, even as the latter company is being abandoned by Roche. | In their ongoing RET inhibitor rivalry, Eli Lilly is pulling further ahead of Blueprint Medicines, even as the latter company is being abandoned by Roche.
Source: www.fiercepharma.comCategories: Hem/Oncs, Latest HeadlinesTweet-
LIBRETTO-431 shows first line selpercatinib provides longer PFS than chemo-immunotherapy in #RET fusion positive NSCLC. Await full data but no surprise. Selective RET inhibitors are among the more effective and better tolerated targeted agents in NSCLC. https://t.co/GU4gbmsOKb
-
-
Mashup Score: 1
IntroductionRearranged during transfection (RET) gene rearrangements occur in 1%–2% of non–small cell lung cancer (NSCLC). Because of the results of the study LIBRETTO-001, selpercatinib has been approved as the first-line treatment for patients with RET fusion–positive advanced NSCLC. Selpercatinib demonstrated to be well tolerated. Despite this, gastrointestinal adverse events (AEs) are…
Source: FrontiersCategories: Hem/Oncs, Latest HeadlinesTweet-
Case report @FrontOncology describes severe small bowel edema and lymphocytic duodenitis attributed to selpercatinib in #RET NSCLC. Improved off therapy and did not recur with dose reduction. Are these effects in part due to prior immunotherapy? https://t.co/amxSxd2YE3
-
-
Mashup Score: 0FDA Approval Summary: Selpercatinib for the treatment of advanced RET fusion-positive solid tumors - 12 month(s) ago
Abstract. On September 21, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo®, Eli Lilly and Company) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Summary of the tumor-agnostic FDA approval of selpercatinib for cancers with #RET fusions @CCR_AACR. Approval 9/21/22 based on LIBRETTO-001 with RR 44% (in tumors other than NSCLC and thyroid, n=41). https://t.co/gRcshM1IRS
-
-
Mashup Score: 4Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications - 12 month(s) ago
Abstract. Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers have obtained FDA tissue-agnostic approval for targeted therapies and immunotherapies. Those include BRAFV600E…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications @CCR_AACR @OncoAlert @mgoudaMD @BlessieNelson @l_buschhorn @damwahida #precisionOncology #RET #BRAF #NTRK https://t.co/06li18qU6s
-
-
Mashup Score: 5
AbstractPurpose:. Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non–small cell lung cancer (NSCLC); however, a multicenter cohort of patients with EGFR-mutant lung cancers treated with osimertinib and selpercatinib for RET fusion–mediated osimertinib resistance has not previously been published.Patients and Methods:. Patients who received…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Report of selpercatinib + osimertinib for #EGFR mt NSCLC with #RET mediated resistance to osimertinib @CCR_AACR. In 14pts, RR 50%, DCR 83%, median treatment duration 7.9m, tolerable profile. Resistance included RET G810S, EGFR C797S, and off-target bypass. https://t.co/jaX1ylRlIm
-
Exceptional responses to selpercatinib in #RET fusion-positive pancreatic cancer described in @JCOPO_ASCO. Rare but certainly actionable events! https://t.co/AQuH67uuxD